Skip to main content
  • SER-109 Investor Event

    View our May 27, 2020 webcast about SER-109

    Read more >

  • Revolutionizing
    Drug Development

    We are creating a new wave of medicines
    powered by the human microbiome.

    Learn about our technology platform

  • Leading a
    Paradigm Shift

    Our Ecobiotic® drugs are a novel approach
    to the treatment of disease.

    Read more about our therapies

  • SER-109:

    Our C. difficile product candidate received FDA
    Breakthrough Therapy designation.

    Learn about SER-109

Biological Diversity by Design

Seres Therapeutics has built a proprietary discovery and design platform that enables us to understand the dysbiosis associated with specific diseases.


Product Pipeline

We are developing a novel class of biological drugs designed to treat disease by restoring the function of a dysbiotic microbiome.


Clinical Trials

We have multiple active clinical studies to evaluate our microbiome therapy clinical candidates.


Back to top